Ekvivalent: Agonisti receptora peptida-1 nalik glukagonu snižavaju ukupni i LDL kolesterol kod pretilih bolesnika s tipom 2 šećerne bolesti

završni specijalistički

• Naslov (engleski): Equivalent: Glucagon-like peptide-1 receptor agonists decrease total and LDL-cholesterol in obese type 2 diabetic patients.
• Autor: Vinko Roso
• Mentor: Tomislav Bulum (mentor)
• Ustanova koja je dodijelila akademski / stručni stupanj: Sveučilište u Zagrebu; Medicinski fakultet; Zagreb
• Datum i država obrane: 2025-01-20, Hrvatska
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly utilized in the management of type 2 diabetes mellitus
(T2DM). GLP-1 RAs have been associated with improvements in serum lipid profiles in clinical trials. Their long-term cardiovascular safety and benefit have also been confirmed in the recently published LEADER trial. In the current study, we assessed the effects of GLP-1 RAs (exenatide and liraglutide) on serum lipid profiles (total, LDL, HDL-cholesterol and triglycerides) of obese patients with T2DM. A total of 85 patients were included in the study (43 on exenatide and 42 on liraglutide) and followed up for 22 and 13 months, respectively. Treatment with exenatide was associated with a significant decrease in total cholesterol from 5.1±1.3 to 4.9±1.2 mmol/L (p=0.02) and LDL-cholesterol from 3.0±1.1 to 2.6±0.8 mmol/L (p=0.01). Treatment with liraglutide was also associated with a significant decrease in total cholesterol from 4.8±1.2 to 4.2±0.8 mmol/L (p=0.001) and LDL-cholesterol from 2.5±0.8 to 2.1±0.5 mmol/L (p=0.006). Treatment with liraglutide and exenatide did not significantly affect HDL-cholesterol and triglyceride levels. The results of our study suggest that treatment with exenatide and liraglutide may significantly reduce total and LDL-cholesterol in obese patients with T2DM.

• Ključne riječi: Glucagon-Like Peptide 1; Diabetes Mellitus/Type 2; Cholesterol/LDL; Cholesterol/HDL; Obesity
• Jezik: engleski
• URN:NBN: urn:nbn:hr:105:488877
• Studijski program: Naziv: Endokrinologija i dijabetologija; Vrsta studija: sveučilišni; Stupanj studija: poslijediplomski specijalistički; Akademski / stručni naziv: sveučilišni/a magistar/magistra endokrinologije i dijabetologije (univ. mag. med.)
• Vrsta resursa: Tekst
• Način izrade datoteke: Izvorno digitalna
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2025-02-24 09:06:52